Recent Company News

• 08:04 PM ET Aug 30, 2026
  

  Hutchmed reports positive high-level results from the SANOVO China Phase III trial (HK$19.83, 0.00)

• 11:47 PM ET Aug 25, 2026
  

  StreetAccount Summary - Hong Kong unusual volume traders

• 02:23 PM ET Aug 20, 2026
  

  Hutchmed initiated buy at Sinolink Securities

• 04:53 PM ET Aug 17, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:15 AM ET Aug 17, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:41 AM ET Aug 17, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:15 AM ET Aug 17, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:07 AM ET Aug 17, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 11:33 PM ET Aug 16, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 08:08 PM ET Aug 16, 2026
  

  HUTCHMED's Orpathys/Tagrisso phase III SAFFRON study shows positive high-level results in EGFR-mutated NSCLCTAGRISSO (HK$19.19, 0.00)